Evaluating risk factors for stomach cancer
Official title: OUR Stomach Health Project: A Pilot Study to Evaluate the Feasibility of Stomach Cancer Risk Assessment for Early Detection and Secondary Prevention
Run by City of Hope Medical Center · NCT06408220 · Data updated 2026-11-12
This study is testing different ways to find out if people aged 40 to 80 from racial minority groups are at high risk for stomach cancer to help catch it early.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 40 Years to 80 Years |
| Sex | All |
| Enrollment | 240 (estimated) |
| Sponsor | City of Hope Medical Center Academic / other |
| Locations | 1 site (Duarte, California) |
| Status | Recruiting |
| Started | June 27, 2024 |
| Main results expected | October 9, 2029 |
| Study ends | October 9, 2029 |
| Registry record updated | March 13, 2026 |
| Trial ID | NCT06408220 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are individuals aged 40 to 80 who identify as Asian, Hispanic, or Black American.
✕Probably not a fit
Patients who are non-Hispanic White or have a history of gastric cancer may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial assesses the effectiveness of various risk assessment methods, including H. pylori breath tests, questionnaires, and endoscopies, to identify individuals at high risk for gastric carcinoma. Participants aged 40 to 80 who identify as racial minorities will undergo these assessments to determine their risk levels. Those identified as high-risk may receive further evaluations, including upper endoscopies, to check for potential gastric cancer. The study aims to enhance early detection and understanding of gastric cancer risk factors in diverse populations.
Why it matters
Potential benefit: If successful, this study could lead to earlier detection and improved outcomes for patients at high risk for stomach cancer.
How similar studies have gone: Other studies have shown promise in using similar risk assessment approaches for early detection of gastric cancer, indicating potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Documented informed consent of the participant and/or legally authorized representative * Assent, when appropriate, will be obtained per institutional guidelines * Age: ≥ 40 years to ≤ 80 years * Identify as a racial minority either Asian, Hispanic, or Black American * Willingness to: * Provide blood samples and undergo upper endoscopy Exclusion Criteria: * Identify as Non-Hispanic White * History of gastric cancer * Known premalignant lesions of the stomach * History of upper endoscopy within 2 years * Women of childbearing potential: Pregnant/ nursing * An employee who is under the direct/indirect supervision of the principal investigator (PI)/a coinvestigator/the study manager * A direct study team member
Where it's running
-
City of Hope Medical Center
Duarte, California, United States Recruiting
Study contacts
- Principal investigator: Yanghee Woo — City of Hope Medical Center
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
PF-08098488 in adults with advanced solid tumors
This study tests PF-08098488 in adults whose cancer has progressed or returned after prior treatment.
-
ENPP1/cGAS and FAP in Solid Tumors in Vietnamese Patients
This Vietnam-based study will test ENPP1, cGAS, and FAP expression in archived tumor samples from Vietnamese adults with solid cancers using immunohistochemistry.
-
Microplastic exposure and progression of stomach precancerous changes
This project will test if adults with higher microplastic exposure are more likely to have precancerous stomach changes or gastric cancer.
-
Disitamab vedotin plus trastuzumab and tislelizumab versus chemotherapy plus trastuzumab (± pembrolizumab) for HER2‑high advanced gastric or gastroesophageal junction adenocarcinoma
This trial tests whether combining disitamab vedotin with trastuzumab and the immunotherapy tislelizumab works better than standard chemotherapy with trastuzumab (with or without pembrolizumab) as first‑line treatment for people with HER2‑high advanced gastric or gastroesophageal junction cancer.
-
Using the PAGODA algorithm to guide FOLFOX dose changes and reduce unplanned chemotherapy delays
This trial will test whether using the PAGODA algorithm to guide dose changes during FOLFOX chemotherapy for people with gastrointestinal cancers can reduce unplanned treatment delays.
-
Examining metastatic lymph nodes in each part of the stomach's mesentery during gastrectomy
This project will see if the number and location of metastatic lymph nodes across the six stomach mesenteries predict outcomes for adults undergoing D2 plus complete mesogastric excision for gastric cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.